EB070

Phase 1Biologic

BBiotech Pharmaceutical Co., Ltd.

EB070 is one of 2 biologic programs targeting Health Adult Subjects. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Health Adult SubjectsNot yet recruiting

Health Adult SubjectsPhase 1

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Health Adult Subjects

#DrugCompanyPhaseTrials

EB070

BBiotech Pharmaceutical Co., Ltd.

Phase 1

1 2

HXN6005

HHelixon Biotechnology (Suzhou) Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Study completion

NCT07413536

Clinical

Trials by Indication[1]

Unspecified1 trial

A Phase Ia Single Ascending-Dose Study of Subcutaneous EB070 Injection in Healthy Volunteers

Not yet recruiting·BBiotech Pharmaceutical Co., Ltd.·Phase 1·NCT07413536·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EB070. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EB070 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EB070. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biotech Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: BBiotech Pharmaceutical Co., Ltd.

EB070

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News